目的 探討胸腺肽腸溶片聯(lián)合復(fù)方硫酸軟骨素治療類風(fēng)濕性關(guān)節(jié)炎的臨床療效。方法 選取2015年5月-2016年5月南陽市骨科醫(yī)院收治的類風(fēng)濕性關(guān)節(jié)炎患者90例，隨機(jī)分為對照組和治療組，每組各45例。對照組口服復(fù)方硫酸軟骨素片，4片/次，3次/d。治療組在對照組的基礎(chǔ)上口服胸腺肽腸溶片，2片/次，3次/d。兩組患者治療時間均為3個月。評價兩組患者臨床療效，同時比較治療前后兩組患者臨床癥狀、關(guān)節(jié)炎相關(guān)指標(biāo)和免疫球蛋白水平。結(jié)果 治療后，對照組和治療組總有效率分別為80.00%和93.33%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組腫脹關(guān)節(jié)數(shù)、壓痛關(guān)節(jié)數(shù)和晨僵時間均出現(xiàn)明顯下降，握力則明顯升高，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。且治療組這些臨床癥狀則明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者類風(fēng)濕因子（RF）、血沉（ESR）和C反應(yīng)蛋白（CRP）水平均顯著降低（P<0.05）。且治療組上述關(guān)節(jié)炎相關(guān)指標(biāo)均明顯低于對照組（P<0.05）。治療后，兩組患者IgG、IgA及IgM均明顯降低（P<0.05）；且治療組上述指標(biāo)含量明顯低于對照組（P<0.05）。結(jié)論 胸腺肽腸溶片聯(lián)合復(fù)方硫酸軟骨素治療類風(fēng)濕性關(guān)節(jié)炎臨床療效確切，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effects of Thymopdypeptide Enteric-Coated Tablets combined with compound chondroitin sulfate in treatment of rheumatoid arthritis. Methods Patients (90 cases) with rheumatoid arthritis in Nanyang Orthopedic Hospital from May 2015 to May 2016 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were po administered with Compound Chondroitin Sulfate Tablets, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Thymopdypeptide Enteric-Coated Tablets on the basis of the control group, 2 tablets/time, three times daily. Patients in two groups were treated for 3 months. After treatment, clinical efficacy was evaluated, and the clinical symptoms, arthritis indexes, and immunoglobulin content in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 80.00% and 93.33%, respectively, and there were differences between two groups (P<0.05). After treatment, the tender and swollen joints, and morning stiffness time in two groups were significantly decreased, but the gripping force was significantly increased, the difference was statistically significant in the same group (P<0.05). And these clinical symptoms in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the RF, ESR and CRP levels in two groups were significantly decreased (P<0.05). And these arthritis indexes in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, the IgG, IgA, and IgM in two groups were significantly decreased (P<0.05). And the immunoglobulin content in the treatment group was obviously lower than that in the control group (P<0.05). Conclusion Thymopdypeptide Enteric-Coated Tablets combined with compound chondroitin sulfate has a good clinical curative effect in treatment of rheumatoid arthritis, which has a certain clinical application value.